Search results
The EURIPID database contains data on official prices of publicly reimbursed medicines, mainly in the out-patient setting, that are published by public authorities in line with the EC Transparency Directive (Council Directive 89/105/EEC 89\105\EC).
- Glossary
A key deliverable of the WHO Collaborating Centre for...
- Noticias
Toggle navigation. Hauptnavigation. About Untermenü für...
- Pharma Price Information
The Pharmacoeconomics Department operates the Pharma Price...
- Members
Gesundheit Österreich GmbH / Austrian National Public Health...
- PPRI Profiles / Briefs
We provide country-specific information in different formats...
- Medicine Prices
Prices of medicines are one of our key working areas. Legal...
- Sitemap
Die Gesundheit Österreich GmbH (GÖG) ist das nationale...
- Pharmaceutical Policy Analysis
Pharmaceutical policy analysis relates to evaluations and...
- Glossary
4 dni temu · Drug prices have rocketed in Europe, with cancer and rare disease medicines in particular pushing up costs, according to a new report from health insurance bodies.. The research, compiled by the European Social Insurance Platform (ESIP) and the Medicine Evaluation Committee (MEDEV) and shared exclusively with POLITICO, shows that European countries including Germany, Spain, Belgium and Latvia ...
23 cze 2020 · In countries without universal healthcare, the high cost of prescription drugs poses an additional threat: unaffordable out-of-pocket costs for individual patients.
23 cze 2020 · Global spending on prescription drugs in 2020 is expected to be ~$1.3 trillion; the United States alone will spend ~$350 billion 1. These high spending rates are expected to increase at a rate of 3–6% annually worldwide.
2 dni temu · The federal government has proven that it can navigate the difficult process of identifying drugs for price negotiation, gathering and analyzing key information, and negotiating with manufacturers.
1 lut 2024 · This report summarizes findings from comparisons of drug prices in the United States and other high-income countries based on 2022 data and presents results for specific types of drugs, including brand-name originator drugs and unbranded generic drugs, and from sensitivity analyses.
27 maj 2021 · Median launch prices increased from $2115 per year (IQR, $928-$17 866) per year in 2008 to $180 007 (IQR, $20 236-409 732) per year in 2021 (Figure). The proportion of drugs priced at $150 000 per year or more was 9% (18/197) in 2008-2013 and 47% (42/89) in 2020-2021.
